Cover Image
市場調查報告書

合成生物學的全球市場:機會及預測 (2014∼2020年)

World Synthetic Biology Market - Opportunities and Forecast, 2014 - 2020

出版商 Allied Market Research 商品編碼 352269
出版日期 內容資訊 英文 172 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
合成生物學的全球市場:機會及預測 (2014∼2020年) World Synthetic Biology Market - Opportunities and Forecast, 2014 - 2020
出版日期: 2016年01月01日 內容資訊: 英文 172 Pages
簡介

全球合成生物學市場,預測將從2015年的52億4,570億萬美元以年複合成長率23%擴大到2020年。政府和民間機關的支援,合成生物學研究機關的增加,DNA定序和合成的成本較低等是擴大市場的主要原因。相對的,生物學的安全性,安全問題則阻礙市場的成長。

本報告提供全球合成生物學市場相關調查,提供您各產品,各技術,各用途,及各地區趨勢,以及到2020年前的市場成長預測,打入市場的主要企業簡介。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特五力分析
  • 價值鏈分析
  • 法律規章的標準
  • 合成生物學相關問題點
  • 市場趨勢

第4章 核甘酸合成概要

  • 核甘酸合成的技術性趨勢
  • 歐洲及北美大型DNA結構的商業性應用範圍
  • 大型參與企業的定位:2014年
  • 核甘酸合成專門的市場趨勢

第5章 各產品市場

  • 概要
  • 合成DNA
  • 合成寡核甘酸
  • 合成遺傳基因
  • 軟件工具
  • Chassis Organisms
  • 合成克隆
  • 合成細胞

第6章 各技術市場

  • 概要
  • 核甘酸合成和定序
  • 生物資訊學技術
  • 微流體技術
  • 遺傳因子工程學

第7章 各用途市場

  • 概要
  • 醫藥品·診斷
  • 生物燃料
  • 化學
  • 生物塑膠
  • 其他

第8章 各地區市場

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東

第9章 企業簡介

  • GEN9 Inc.
  • Codexis Inc.
  • OriGene Technologies, Inc.
  • Synthetic Genomics, Inc.
  • Thermo fisher Scientific
  • GENEWIZ, Inc.
  • Eurofins Scientific, Inc.
  • Integrated DNA Technologies, Inc.
  • DNA2.0, Inc.
  • Pareto Biotechnologies
  • Synthorx, Inc.
  • TeselaGen Biotechnology
  • Editas Medicine, Inc.
  • GenScript Corporation
  • Twist Bioscience
  • GeneWorks Pty Ltd.
  • Proterro, Inc.
  • Blue heron (OriGene technologies Inc.)

圖表

目錄

Title: Synthetic Biology Market By Products(Synthetic DNA, Synthetic genes, Software tools, Synthetic cells, Chassis organisms), and Technology (Genetic Engineering, Bioinformatics, Microfluidics) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022.

Synthetic biology is a novel area of research that is the amalgamation of multiple disciplines such as molecular biology, biotechnology, biophysics and genetic engineering among others. There are chiefly two approaches used in synthetic biology namely, top down approach and bottom up approach. Top-down approach involves the re-design and fabrication of existing biological systems for producing synthetic products. Bottom-up approach involves designing and construction of de novo biological systems or devices that do not exist in nature. An impending need to understand the functioning of genetic elements, cells and biological processes has led to the emergence of synthetic biology. Synthetic biology products are used across many industries, including pharmaceutical & diagnostics, energy, bioplastics and environment.

World synthetic biology market was valued at $ 5,245.7 million in 2015, growing at a CAGR of 23% during the forecast period. Assistance from government and private organizations, rising number of synthetic biology research entities and declining cost of DNA sequencing & synthesizing are the major factors driving the market growth. On the contrary, bio-safety & bio-security issues, would hinder the market growth. The issues related to the misuse of synthetic biology or possibilities of accidental release of pathogens into free atmosphere would remain as a key challenge worldwide. However, rising demand for bio-fuels, growing awareness in emerging economies and rising R&D investments for synthetic drugs and vaccines would offer lucrative opportunities in the market.

Based on geography, the market is segmented across North America, Europe, Asia-Pacific and LAMEA regions. In 2015, Europe was the leading geography in terms of revenue generation followed by North America. Further, Europe would continue to maintain its lead position through 2020 owing to constant support from European government and private organizations, establishment of small start-ups and investment by leading companies especially in the biofuel segment. Asia Pacific is projected as the fastest growing market owing to increasing number of research entities.

The report provides a comprehensive analysis of the leading companies operating in the world synthetic biology market. Key companies profiled in the report are Thermo Fischer Scientific, GenScript, DNA2.0, Integrated DNA technologies, Eurofins Scientific, Inc., Origene technologies, Scientific genomics Inc. Editas Medicine, Inc., Pareto Biotechnologies, Blue heron, TeselaGen, Twist biosciences, Syntrox Inc., and others.

KEY BENEFITS:

This report provides an extensive analysis of the current and emerging market trends and dynamics in the world synthetic biology market.

The report provides a detailed analysis of the current market and estimations during 20142020, which would enable the stakeholders to capitalize on the prevailing market opportunities.

The synthetic biology market scenario has been comprehensively analyzed in accordance to key geographical regions.

The key market players operating in the market have been profiled in the report, and their strategies have been thoroughly analyzed to understand the competitive outlook of the market.

Competitive intelligence highlights the business practices followed by leading market players across geographies.

SWOT analysis enables to study the internal environment of the leading companies for strategy formulation

SYNTHETIC BIOLOGY MARKET KEY SEGMENTS:

The world Synthetic Biology market is segmented as:

By Products

  • Synthetic DNA
  • Synthetic oligos
  • Synthetic genes
  • Software tools
  • Chassis organisms
  • Synthetic clones
  • Synthetic cells

By Technology

  • Nucleotide synthesis and sequencing
  • Bioinformatics
  • Microfluidics
  • Genetic engineering

By Application

  • Pharmaceuticals and diagnostics
  • Chemicals
  • Biofuels
  • Bioplastics
  • Others (Environment, agriculture & aquaculture)

By Geography

  • North America
  • Europe
  • Asia Pacific
  • LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond: what to expect by 2025
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
    • 3.2.3. Top winning strategies
  • 3.3. Porters five force analysis
    • 3.3.1. Fewer suppliers lead to higher bargaining power of suppliers
    • 3.3.2. Higher buyer concentration leads to low bargaining power
    • 3.3.3. Low threat of substitutes due to lack of superior alternatives
    • 3.3.4. Low threat of new entrants due to high capital investment
    • 3.3.5. Moderate competitive rivalry
  • 3.4. Value chain analysis
    • 3.4.1. Research and product development
    • 3.4.2. Product testing
    • 3.4.3. Manufacturing
    • 3.4.4. End users
  • 3.5. Regulatory norms
  • 3.6. Concerns related to synthetic biology
  • 3.7. Market Dynamics
    • 3.7.1. Drivers
    • 3.7.1.1. Funding from government and Private organizations
    • 3.7.1.2. Rising number of research facilities
    • 3.7.1.3. Rising count of new entrants
    • 3.7.1.4. Declining cost of DNA Sequencing
  • 3.7.2. Restraints
    • 3.7.2.1. Bio-safety and Bio-security Issues
    • 3.7.2.2. Ethical concerns and stringent regulations
  • 3.7.3. Opportunities
    • 3.7.3.1. growing demand of bio-fuels and Bioplastics
    • 3.7.3.2. increasing research activities in Asia Pacific region
    • 3.7.3.3. rising R&D investments

CHAPTER 4: OVERVIEW OF NUCLEOTIDE SYNTHESIS

  • 4.1. Technological trends in nucleotide synthesis
  • 4.2. Commercial application scope for large DNA constructs in Europe and North America
    • 4.2.1. Antibody engineering
    • 4.2.2. Metabolic engineering
    • 4.2.3. Pathway engineering
    • 4.2.4. Other potential application
  • 4.3. Top players positioning, 2014, (Focus on nucleotide synthesis)
  • 4.4. Market dynamics specific to nucleotide synthesis
    • 4.4.1. Drivers
      • 4.4.1.1. Technical advancements in integrated sequencing
      • 4.4.1.2. Growing demand for large DNA constructs
      • 4.4.1.3. Increasing accountability of government funding
    • 4.4.2. Restraints
      • 4.4.2.1. High cost and longer duration of nucleotide synthesis
      • 4.4.2.2. Absence of regulatory guidelines
    • 4.4.3. Opportunities
      • 4.4.3.1. Exploring opportunities in European countries

CHAPTER 5: WORLD SYNTHETIC BIOLOGY MARKET, BY PRODUCT

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Synthetic DNA
    • 5.2.1. Key market trends
    • 5.2.2. Key growth factors and opportunities
    • 5.2.3. Market size and forecast
  • 5.3. Synthetic Oligonucleotides
    • 5.3.1. Key market trends
    • 5.3.2. Key growth factors and opportunities
    • 5.3.3. Market size and forecast
  • 5.4. Synthetic Genes
    • 5.4.1. Key market trends
    • 5.4.2. Key growth factors and opportunities
    • 5.4.3. Market size and forecast
  • 5.5. Software tools
    • 5.5.1. Key market trends
    • 5.5.2. Key growth factors and opportunities
    • 5.5.3. Market size and forecast
  • 5.6. Chassis Organisms
    • 5.6.1. Key market trends
    • 5.6.2. Key growth factors and opportunities
    • 5.6.3. Market size and forecast
  • 5.7. Synthetic Clones
    • 5.7.1. Key market trends
    • 5.7.2. Key growth factors and opportunities
    • 5.7.3. Market size and forecast
  • 5.8. Synthetic cells
    • 5.8.1. Key market trends
    • 5.8.2. Key growth factors and opportunities
    • 5.8.3. Market size and forecast

CHAPTER 6: WORLD SYNTHETIC BIOLOGY MARKET, BY TECHNOLOGY

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Nucleotide synthesis and sequencing
    • 6.2.1. Key market trends
    • 6.2.2. Key growth factors and opportunities
    • 6.2.3. Market size and forecast
  • 6.3. Bioinformatics technologies
    • 6.3.1. Key market trends
    • 6.3.2. Key growth factors and opportunities
    • 6.3.3. Market size and forecast
  • 6.4. Microfluidics technologies
    • 6.4.1. Key market trends
    • 6.4.2. Key growth factors and opportunities
    • 6.4.3. Market size and forecast
  • 6.5. Genetic engineering
    • 6.5.1. Key market trends
    • 6.5.2. Key growth factors and opportunities
    • 6.5.3. Market size and forecast

CHAPTER 7: WORLD SYNTHETIC BIOLOGY MARKET, BY APPLICATION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Pharmaceuticals & diagnostics
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.3. Market size and forecast
  • 7.3. Biofuels
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Market size and forecast
  • 7.4. Chemicals
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Market size and forecast
  • 7.5. Bioplastics
    • 7.5.1. Key market trends
    • 7.5.2. Key growth factors and opportunities
    • 7.5.3. Market size and forecast
  • 7.6. Others (agriculture, bioremediation and aquaculture)
    • 7.6.1. Market size and forecast

CHAPTER 8: WORLD SYNTHETIC BIOLOGY MARKET, BY GEOGRAPHY

  • 8.1. Overview
    • 8.1.1. Market size and forecast
  • 8.2. North America
    • 8.2.1. Key market trends
    • 8.2.2. Key growth factors and opportunities
    • 8.2.3. Market size and forecast
  • 8.3. Europe
    • 8.3.1. Key market trends
    • 8.3.2. Key growth factors and opportunities
    • 8.3.3. Market size and forecast
  • 8.4. Asia Pacific
    • 8.4.1. Key market trends
    • 8.4.2. Key growth factors and opportunities
    • 8.4.3. Market size and forecast
  • 8.5. LAMEA
    • 8.5.1. Key market trends
    • 8.5.2. Key growth factors and opportunities
    • 8.5.3. Market size and forecast

CHAPTER 9: COMPANY PROFILES

  • 9.1. GEN9. Inc.
    • 9.1.1. Company overview
    • 9.1.2. Company snapshot
    • 9.1.3. Strategic moves and developments
    • 9.1.4. SWOT analysis of Gen9 Inc.
  • 9.2. Codexis Inc.
    • 9.2.1. Company overview
    • 9.2.2. Company snapshot
    • 9.2.3. Business performance
    • 9.2.4. Strategic moves and developments
    • 9.2.5. SWOT analysis of Codexis
  • 9.3. OriGene Technologies, Inc.
    • 9.3.1. Company overview
    • 9.3.2. Company snapshot
    • 9.3.3. Strategic moves and developments
    • 9.3.4. SWOT analysis of OriGene
  • 9.4. Synthetic Genomics, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Company snapshot
    • 9.4.3. Strategic moves and developments
    • 9.4.4. SWOT analysis of Synthetic Genomics
  • 9.5. Thermo fisher Scientific
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Business performance
    • 9.5.4. Strategic moves and developments
    • 9.5.5. SWOT analysis of Thermo fisher Scientific
  • 9.6. GENEWIZ, Inc.
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Strategic moves and development
    • 9.6.4. SWOT analysis of GENEWIZ, Inc.
  • 9.7. Eurofins Scientific, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Services portfolio
    • 9.7.4. Strategic moves and developments
    • 9.7.5. Business performance
    • 9.7.6. SWOT analysis of Eurofins Scientific, Inc.
  • 9.8. Integrated DNA Technologies, Inc.
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Services Portfolio
    • 9.8.4. Strategic moves and development
    • 9.8.5. SWOT analysis of Integrated DNA Technologies, Inc.
  • 9.9. DNA2.0, Inc.
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Services portfolio
    • 9.9.4. Strategic moves and development
    • 9.9.5. SWOT analysis of DNA2.0, Inc.
  • 9.10. Pareto Biotechnologies
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Services Portfolio
    • 9.10.4. Strategic moves and development
    • 9.10.5. SWOT analysis of Pareto Biotechnologies
  • 9.11. Synthorx, Inc.
    • 9.11.1. Company overview
    • 9.11.2. Company snapshot
    • 9.11.3. Services portfolio
    • 9.11.4. SWOT analysis of Synthorx, Inc.
  • 9.12. TeselaGen Biotechnology
    • 9.12.1. Company overview
    • 9.12.2. Company snapshot
    • 9.12.3. Services portfolio
    • 9.12.4. Strategic moves and developments
    • 9.12.5. SWOT Analysis of TeselaGen Biotechnology.
  • 9.13. Editas Medicine, Inc.
    • 9.13.1. Company overview
    • 9.13.2. Company snapshot
    • 9.13.3. Services portfolio
    • 9.13.4. Strategic moves and development
    • 9.13.5. SWOT analysis of Editas Medicine, Inc.
  • 9.14. GenScript Corporation
    • 9.14.1. Company overview
    • 9.14.2. Company snapshot
    • 9.14.3. Strategic moves and developments
    • 9.14.4. SWOT analysis of GenScript
  • 9.15. Twist Bioscience
    • 9.15.1. Company overview
    • 9.15.2. Company snapshot
    • 9.15.3. Services portfolio
    • 9.15.4. Strategic moves and developments
    • 9.15.5. SWOT analysis of Twist Bioscience
  • 9.16. GeneWorks Pty Ltd.
    • 9.16.1. Company overview
    • 9.16.2. Company snapshot
    • 9.16.3. Services portfolio
    • 9.16.4. SWOT analysis of GeneWorks Pty. Ltd.
  • 9.17. Proterro, Inc.
    • 9.17.1. Company overview
    • 9.17.2. Company snapshot
    • 9.17.3. Services portfolio
    • 9.17.4. Strategic moves and developments
    • 9.17.5. SWOT analysis of Proterro, Inc.
  • 9.18. Blue heron (OriGene technologies Inc.)
    • 9.18.1. Company overview
    • 9.18.2. Company snapshot
    • 9.18.3. Service portfolio of Blue heron (OriGene technologies Inc.)
    • 9.18.4. SWOT analysis of Blue heron (OriGene technologies Inc.)

List of Tables

  • TABLE 1: WORLD SYNTHETIC BIOLOGY MARKET, MODERATE GROWTH SCENARIO, VALUE, 2020 2025 ($MILLION)
  • TABLE 2: WORLD SYNTHETIC BIOLOGY MARKET RAPID GROWTH SCENARIO, VALUE, 2020 2025 ($MILLION)
  • TABLE 3: WORLD SYNTHETIC BIOLOGY MARKET, DIMINISHING GROWTH SCENARIO, VALUE, 2020 2025 ($MILLION)
  • TABLE 4: COMMERCIAL APPLICATION OF SYNTHETIC BIOLOGY IN DERIVING RENEWABLE ENERGY
  • TABLE 5: WORLD SYNTHETIC BIOLOGY MARKET REVENUE, BY PRODUCT, 2014 2020 ($MILLION)
  • TABLE 6: WORLD SYNTHETIC DNA MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 7: WORLD SYNTHETIC OLIGONUCLEOTIDES MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 8: WORLD SYNTHETIC GENES MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 9: SOFTWARE TOOLS DEVELOPED FOR THE MODELING AND SIMULATION OF BIOLOGICAL INTERACTIONS
  • TABLE 10: WORLD SYNTHETIC BIOLOGY SOFTWARE TOOLS MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 11: WORLD CHASSIS ORGANISMS MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 12: WORLD SYNTHETIC CLONES MARKET REVENUE, BY GEOGRAPHY,2014 2020 ($MILLION)
  • TABLE 13: WORLD SYNTHETIC CELLS MARKET REVENUE BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 14: WORLD SYNTHETIC BIOLOGY MARKET REVENUE BY TECHNOLOGY, 2014 2020 ($MILLION)
  • TABLE 15: WORLD NUCLEOTIDE SYNTHESIS AND SEQUENCING MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 16: WORLD SYNTHETIC BIOLOGY BIOINFORMATICS TECHNOLOGIES MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 17: WORLD SYNTHETIC BIOLOGY MICROFLUIDICS TECHNOLOGIES MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 18: WORLD GENETIC ENGINEERING MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 19: WORLD SYNTHETIC BIOLOGY MARKET REVENUE, BY APPLICATION, 2014 2020 ($MILLION)
  • TABLE 20: SYNTHETIC BIOLOGY PHARMACEUTICALS & DIAGNOSTICS APPLICATION MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 21: SYNTHETIC BIOLOGY BIOFUELS INDUSTRY APPLICATION MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 22: SYNTHETIC BIOLOGY CHEMICAL INDUSTRY APPLICATION MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 23: SYNTHETIC BIOLOGY BIOPLSATICS INDUSTRY APPLICATION MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 24: SYNTHETIC BIOLOGY OTHER APPLICATIONS MARKET REVENUE, BY GEOGRAPHY, 2014 2020 ($MILLION)
  • TABLE 25: NORTH AMERICA SYNTHETIC BIOLOGY MARKET REVENUE, BY TECHNOLOGY, 2014 - 2020 ($MILLION)
  • TABLE 26: EUROPE SYNTHETIC BIOLOGY MARKET REVENUE, BY TECHNOLOGY, 2014 - 2020 ($MILLION)
  • TABLE 27: ASIA PACIFIC SYNTHETIC BIOLOGY MARKET REVENUE, BY APPLICATION, 2014 - 2020 ($MILLION)
  • TABLE 28: LAMEA SYNTHETIC BIOLOGY MARKET REVENUE, BY TECHNOLOGY, 2014 - 2020 ($MILLION)
  • TABLE 29: GEN9 INC., SNAPSHOT
  • TABLE 30: CODEXIS SNAPSHOT
  • TABLE 31: ORIGENE SNAPSHOT
  • TABLE 32: SYNTHETIC GENOMICS SNAPSHOT
  • TABLE 33: COMPANY SNAPSHOT OF THERMO FISHER SCIENTIFIC
  • TABLE 34: COMPANY SNAPSHOT
  • TABLE 35: EUROFINS SCIENTIFIC, INC. SNAPSHOT
  • TABLE 36: SERVICE PORTFOLIO OF EUROFINS SCIENTIFIC, INC.
  • TABLE 37: COMPANY SNAPSHOT OF INTEGRATED DNA TECHNOLOGIES, INC
  • TABLE 38: SERVICES PORTFOLIO OF INTEGRATED DNA TECHNOLOGIES, INC.
  • TABLE 39: COMPANY SNAPSHOT OF DNA2.0, INC.
  • TABLE 40: SERVICES PORTFOLIO OF DNA2.0, INC.
  • TABLE 41: COMPANY SNAPSHOT OF PARENTO BIOTECHNOLOGIES
  • TABLE 42: SERVICES PORTFOLIO OF PARENTO BIOTECHNOLOGIES
  • TABLE 43: COMPANY SNAPSHOT OF SYNTHORX, INC.
  • TABLE 44: SERVICES PORTFOLIO OF SYNTHORX, INC.
  • TABLE 45: COMPANY SNAPSHOT OF TESELAGEN BIOTECHNOLOGY
  • TABLE 46: SERVICES PORTFOLIO OF TESELAGEN BIOTECHNOLOGY
  • TABLE 47: COMPANY SNAPSHOT OF EDITAS MEDICINE, INC.
  • TABLE 48: SERVICES PORTFOLIO OF EDITAS MEDICINE, INC.
  • TABLE 49: GENSCRIPT SNAPSHOT
  • TABLE 50: COMPANY SNAPSHOT OF TWIST BIOSCIENCE
  • TABLE 51: SERVICES PORTFOLIO OF TWIST BIOSCIENCE
  • TABLE 52: COMPANY SNAPSHOT OF GENEWORKS PTY. LTD.
  • TABLE 53: SERVICES PORTFOLIO OF GENEWORKS PTY. LTD.
  • TABLE 54: COMPANY SNAPSHOT OF PROTERRO, INC.
  • TABLE 55: SERVICES PORTFOLIO OF PROTERRO, INC.
  • TABLE 56: COMPANY SNAPSHOT OF BLUE HERON (ORIGENE TECHNOLOGIES INC.)
  • TABLE 57: SERVICE PORTFOLIO OF BLUE HERON (ORIGENE TECHNOLOGIES INC.)

List of Figures

  • FIG. 1: IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020 - 2025)
  • FIG. 2: IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020 - 2025)
  • FIG. 3: IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020 - 2025)
  • FIG. 4: TOP IMPACTING FACTORS (2014-2020)
  • FIG. 5: TOP INVESTMENT POCKETS
  • FIG. 6: TOP WINNING STRATEGIES (2013-2015)
  • FIG. 7: PORTERS FIVE FORCE ANALYSIS
  • FIG. 8: VALUE CHAIN ANALYSIS
  • FIG. 9: PLAYER POSITIONING OF SYNTHETIC BIOLOGY MARKET (2013)
  • FIG. 10: BIOFUEL PRODUCTION BY MAJOR REGIONS (2011 2020)
  • FIG. 11: SWOT ANALYSIS OF GEN9, INC.
  • FIG. 12: REVENUE GENERATED BY CODEXIS, INC., (2014-2020)
  • FIG. 13: SWOT ANALYSIS OF CODEXIS
  • FIG. 14: SWOT ANALYSIS OF ORIGENE TECHNOLOGIES, INC.
  • FIG. 15: SWOT ANALYSIS OF SYNTHETIC GENOMICS
  • FIG. 16: REVENUE GENERATED BY THERMO FISHER SCIENTIFIC (2012-2014)
  • FIG. 17: SWOT ANALYSIS OF THERMOFISHER SCIENTIFIC
  • FIG. 18: SWOT ANALYSIS OF GENEWIZ, INC.
  • FIG. 19: REVENUE GENERATED BY EUROFINS SCIENTIFIC (2012-2014)
  • FIG. 20: SWOT ANALYSIS OF EUROFINS SCIENTIFIC, INC.
  • FIG. 21: SWOT ANALYSIS OF INTEGRATED DNA TECHNOLOGIES, INC.
  • FIG. 22: SWOT ANALYSIS OF DNA2.0, INC.
  • FIG. 23: SWOT ANALYSIS OF PARENTO BIOTECHNOLOGIES
  • FIG. 24: SWOT ANALYSIS OF SYNTHORX, INC.
  • FIG. 25: SWOT ANALYSIS OF TESELAGEN BIOTECHNOLOGY.
  • FIG. 26: SWOT ANALYSIS OF EDITAS MEDICINE, INC.
  • FIG. 27: SWOT ANALYSIS OF GENSCRIPT
  • FIG. 28: SWOT ANALYSIS OF TWIST BIOSCIENCE
  • FIG. 29: SWOT ANALYSIS OF GENEWORKS PTT. LTD.
  • FIG. 30: SWOT ANALYSIS OF PROTERRO, INC.
  • FIG. 31: SWOT ANALYSIS OF BLUE HERON (ORIGENE TECHNOLOGIES INC.)
Back to Top